Cargando…

Chimeric vaccine design against the epidemic Langya Henipavirus using immunoinformatics and validation via immune simulation approaches

In July 2022, a new virus called Langya virus (LayV) was discovered in China in patients who had a fever. This virus is a type of Henipavirus (HNV) and is considered a potential threat as it could spread from animals to humans. It causes respiratory disease with symptoms including fever, coughing, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fahira, Aamir, Amin, Rana Sherdil, Arshad, Uzma, Khan, Muhammad Idrees, Shah Syed, Ali Alamdar, Alshammari, Abdulrahman, Yang, Qiangzhen, Wang, Zhuo, Ali, Liaqat, Shi, Yongyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361368/
https://www.ncbi.nlm.nih.gov/pubmed/37484358
http://dx.doi.org/10.1016/j.heliyon.2023.e17376
_version_ 1785076202484006912
author Fahira, Aamir
Amin, Rana Sherdil
Arshad, Uzma
Khan, Muhammad Idrees
Shah Syed, Ali Alamdar
Alshammari, Abdulrahman
Yang, Qiangzhen
Wang, Zhuo
Ali, Liaqat
Shi, Yongyong
author_facet Fahira, Aamir
Amin, Rana Sherdil
Arshad, Uzma
Khan, Muhammad Idrees
Shah Syed, Ali Alamdar
Alshammari, Abdulrahman
Yang, Qiangzhen
Wang, Zhuo
Ali, Liaqat
Shi, Yongyong
author_sort Fahira, Aamir
collection PubMed
description In July 2022, a new virus called Langya virus (LayV) was discovered in China in patients who had a fever. This virus is a type of Henipavirus (HNV) and is considered a potential threat as it could spread from animals to humans. It causes respiratory disease with symptoms including fever, coughing, and fatigue and is closely linked to two other henipaviruses that are known to infect humans, namely Hendra and Nipah viruses. These viruses may cause fatal respiratory illnesses. Investigators believe that the LayV is spread by shrews, and may have infected humans directly or via an intermediary species. Thus, the use of vaccines or immunizations against LayV is an alternate strategy for disease prevention. In this study, we employed various immunoinformatics methods to predict B cell, HTL and T cell epitopes from the LayV proteome in order to find the most promising candidate for a LayV vaccine. The most potent epitopes that are immunogenic and non-allergenic were joined with each other through suitable linkers. Human β-defensin 2 was employed as an adjuvant to increase the immunogenicity of the vaccine construct. The final sequence of a multi-epitope vaccine construct was modelled for docking with TLRs. Concisely, our results suggest that the docked complexes of vaccine-TLRs seemed to be stable. Additionally, in silico cloning was done using E. coli as the host in order to validate the expression of our designed vaccine construct. The GC content of 54.39% and CAI value of 0.94 revealed that the vaccine component expresses efficiently in the host. This study presents the novel vaccine construct for LayV which will be essential for further experimental validations to confirm the immunogenicity and safety of the proposed vaccine structure, and eventually to treat HNV-related diseases.
format Online
Article
Text
id pubmed-10361368
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103613682023-07-22 Chimeric vaccine design against the epidemic Langya Henipavirus using immunoinformatics and validation via immune simulation approaches Fahira, Aamir Amin, Rana Sherdil Arshad, Uzma Khan, Muhammad Idrees Shah Syed, Ali Alamdar Alshammari, Abdulrahman Yang, Qiangzhen Wang, Zhuo Ali, Liaqat Shi, Yongyong Heliyon Research Article In July 2022, a new virus called Langya virus (LayV) was discovered in China in patients who had a fever. This virus is a type of Henipavirus (HNV) and is considered a potential threat as it could spread from animals to humans. It causes respiratory disease with symptoms including fever, coughing, and fatigue and is closely linked to two other henipaviruses that are known to infect humans, namely Hendra and Nipah viruses. These viruses may cause fatal respiratory illnesses. Investigators believe that the LayV is spread by shrews, and may have infected humans directly or via an intermediary species. Thus, the use of vaccines or immunizations against LayV is an alternate strategy for disease prevention. In this study, we employed various immunoinformatics methods to predict B cell, HTL and T cell epitopes from the LayV proteome in order to find the most promising candidate for a LayV vaccine. The most potent epitopes that are immunogenic and non-allergenic were joined with each other through suitable linkers. Human β-defensin 2 was employed as an adjuvant to increase the immunogenicity of the vaccine construct. The final sequence of a multi-epitope vaccine construct was modelled for docking with TLRs. Concisely, our results suggest that the docked complexes of vaccine-TLRs seemed to be stable. Additionally, in silico cloning was done using E. coli as the host in order to validate the expression of our designed vaccine construct. The GC content of 54.39% and CAI value of 0.94 revealed that the vaccine component expresses efficiently in the host. This study presents the novel vaccine construct for LayV which will be essential for further experimental validations to confirm the immunogenicity and safety of the proposed vaccine structure, and eventually to treat HNV-related diseases. Elsevier 2023-06-15 /pmc/articles/PMC10361368/ /pubmed/37484358 http://dx.doi.org/10.1016/j.heliyon.2023.e17376 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Fahira, Aamir
Amin, Rana Sherdil
Arshad, Uzma
Khan, Muhammad Idrees
Shah Syed, Ali Alamdar
Alshammari, Abdulrahman
Yang, Qiangzhen
Wang, Zhuo
Ali, Liaqat
Shi, Yongyong
Chimeric vaccine design against the epidemic Langya Henipavirus using immunoinformatics and validation via immune simulation approaches
title Chimeric vaccine design against the epidemic Langya Henipavirus using immunoinformatics and validation via immune simulation approaches
title_full Chimeric vaccine design against the epidemic Langya Henipavirus using immunoinformatics and validation via immune simulation approaches
title_fullStr Chimeric vaccine design against the epidemic Langya Henipavirus using immunoinformatics and validation via immune simulation approaches
title_full_unstemmed Chimeric vaccine design against the epidemic Langya Henipavirus using immunoinformatics and validation via immune simulation approaches
title_short Chimeric vaccine design against the epidemic Langya Henipavirus using immunoinformatics and validation via immune simulation approaches
title_sort chimeric vaccine design against the epidemic langya henipavirus using immunoinformatics and validation via immune simulation approaches
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361368/
https://www.ncbi.nlm.nih.gov/pubmed/37484358
http://dx.doi.org/10.1016/j.heliyon.2023.e17376
work_keys_str_mv AT fahiraaamir chimericvaccinedesignagainsttheepidemiclangyahenipavirususingimmunoinformaticsandvalidationviaimmunesimulationapproaches
AT aminranasherdil chimericvaccinedesignagainsttheepidemiclangyahenipavirususingimmunoinformaticsandvalidationviaimmunesimulationapproaches
AT arshaduzma chimericvaccinedesignagainsttheepidemiclangyahenipavirususingimmunoinformaticsandvalidationviaimmunesimulationapproaches
AT khanmuhammadidrees chimericvaccinedesignagainsttheepidemiclangyahenipavirususingimmunoinformaticsandvalidationviaimmunesimulationapproaches
AT shahsyedalialamdar chimericvaccinedesignagainsttheepidemiclangyahenipavirususingimmunoinformaticsandvalidationviaimmunesimulationapproaches
AT alshammariabdulrahman chimericvaccinedesignagainsttheepidemiclangyahenipavirususingimmunoinformaticsandvalidationviaimmunesimulationapproaches
AT yangqiangzhen chimericvaccinedesignagainsttheepidemiclangyahenipavirususingimmunoinformaticsandvalidationviaimmunesimulationapproaches
AT wangzhuo chimericvaccinedesignagainsttheepidemiclangyahenipavirususingimmunoinformaticsandvalidationviaimmunesimulationapproaches
AT aliliaqat chimericvaccinedesignagainsttheepidemiclangyahenipavirususingimmunoinformaticsandvalidationviaimmunesimulationapproaches
AT shiyongyong chimericvaccinedesignagainsttheepidemiclangyahenipavirususingimmunoinformaticsandvalidationviaimmunesimulationapproaches